Boston Scientific Target of Unusually Large Options Trading (NYSE:BSX)

Boston Scientific Co. (NYSE:BSX) was the recipient of some unusual options trading activity on Monday. Stock traders bought 16,833 call options on the stock. This represents an increase of 78% compared to the average daily volume of 9,470 call options.

Insider Activity at Boston Scientific

In other news, EVP John Bradley Sorenson sold 1,201 shares of the business’s stock in a transaction that occurred on Friday, February 14th. The stock was sold at an average price of $106.31, for a total transaction of $127,678.31. Following the sale, the executive vice president now directly owns 25,443 shares in the company, valued at approximately $2,704,845.33. The trade was a 4.51 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, EVP Arthur C. Butcher sold 17,313 shares of the business’s stock in a transaction on Monday, February 3rd. The shares were sold at an average price of $101.80, for a total transaction of $1,762,463.40. Following the completion of the sale, the executive vice president now directly owns 5,502 shares in the company, valued at $560,103.60. This trade represents a 75.88 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 133,183 shares of company stock worth $13,948,476 in the last ninety days. 0.50% of the stock is currently owned by insiders.

Institutional Trading of Boston Scientific

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Moody National Bank Trust Division raised its holdings in shares of Boston Scientific by 34.8% in the 1st quarter. Moody National Bank Trust Division now owns 3,756 shares of the medical equipment provider’s stock valued at $379,000 after purchasing an additional 970 shares during the period. Central Pacific Bank Trust Division boosted its stake in shares of Boston Scientific by 13.3% during the 1st quarter. Central Pacific Bank Trust Division now owns 30,501 shares of the medical equipment provider’s stock worth $3,077,000 after acquiring an additional 3,575 shares during the period. Versant Capital Management Inc raised its stake in Boston Scientific by 134.9% in the 1st quarter. Versant Capital Management Inc now owns 5,435 shares of the medical equipment provider’s stock valued at $548,000 after acquiring an additional 3,121 shares during the period. Hobart Private Capital LLC acquired a new stake in Boston Scientific during the 1st quarter valued at $234,000. Finally, Neville Rodie & Shaw Inc. acquired a new position in shares of Boston Scientific in the first quarter valued at $2,341,000. 89.07% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several research firms have recently commented on BSX. Royal Bank of Canada increased their price target on shares of Boston Scientific from $105.00 to $116.00 and gave the company an “outperform” rating in a research note on Thursday, February 6th. Citigroup lifted their target price on Boston Scientific from $107.00 to $122.00 and gave the company a “buy” rating in a research note on Thursday, February 6th. StockNews.com cut Boston Scientific from a “buy” rating to a “hold” rating in a report on Saturday, March 8th. Piper Sandler raised their target price on shares of Boston Scientific from $95.00 to $115.00 and gave the company an “overweight” rating in a research note on Monday, February 3rd. Finally, TD Cowen increased their price objective on shares of Boston Scientific from $100.00 to $110.00 and gave the company a “buy” rating in a report on Thursday, December 12th. Two investment analysts have rated the stock with a hold rating, twenty-one have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $108.91.

Boston Scientific Stock Up 0.5 %

Shares of BSX stock traded up $0.45 on Monday, hitting $90.15. 4,089,823 shares of the stock were exchanged, compared to its average volume of 6,181,892. The business has a 50-day moving average of $101.90 and a 200 day moving average of $93.71. Boston Scientific has a fifty-two week low of $66.80 and a fifty-two week high of $107.17. The firm has a market capitalization of $133.34 billion, a P/E ratio of 72.12, a price-to-earnings-growth ratio of 2.79 and a beta of 0.73. The company has a current ratio of 1.08, a quick ratio of 1.02 and a debt-to-equity ratio of 0.41.

Boston Scientific (NYSE:BSX) last released its quarterly earnings results on Wednesday, February 5th. The medical equipment provider reported $0.70 earnings per share for the quarter, topping analysts’ consensus estimates of $0.65 by $0.05. Boston Scientific had a return on equity of 17.80% and a net margin of 11.07%. Equities analysts anticipate that Boston Scientific will post 2.85 EPS for the current year.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.